TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04454190

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of genetic material
Description: Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of genetic material
Description: Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
Study: NCT05658315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApplTree smartphone application
Description: ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
Study: NCT05571319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: Glucophage XR 500 mg
Study: NCT04454190

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of genetic material
Description: Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
Study: NCT05561660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFO device closure
Description: Participants randomized into this group will take PFO device closure.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: Participants randomized into this group will take aspirin 200mg qd for 6 months.
Study: NCT04424602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclo phosphamide
Description: 500mg vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate
Description: 500mg film-coated tablets.
Study: NCT05684107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPACK block
Description: the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
Study: NCT02124226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg/week + folic acid the day after

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT05037799

Intervention type: DRUG
Intervention: Rb-82 Radioisotope
Description: Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight

Intervention type: DRUG
Intervention: Rb-82 Radioisotope
Description: Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight

Intervention type: DRUG
Intervention: Rb-82 Radioisotope
Description: Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight

Intervention type: DRUG
Intervention: Rb-82 Radioisotope
Description: Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
Study: NCT04659213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esolution catheter
Description: esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
Study: NCT06316024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Description: The participants drink 240 mL of water approximately 6-8 hours after surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: juice/sport drink group
Description: The participants drink 240 mL of juice/sport drink approximately 6-8 hours after surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum group
Description: The participants eat chewing gum approximately 6-8 hours after surgery
Study: NCT06382376

Intervention type: PROCEDURE
Intervention: Intrathecal morphine administered group, Four quadrant transversus abdominis plane block applied group
Description: Intrathecal morphine administered group and Four quadrant transversus abdominis plane block applied group

Intervention type: PROCEDURE
Intervention: Intrathecal morphine administered group, Four quadrant transversus abdominis plane block applied group
Description: Intrathecal morphine administered group and Four quadrant transversus abdominis plane block applied group
Study: NCT05213767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2916 injection
Description: TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
Study: NCT06282133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Experiments for Intolerance of Uncertainty
Description: Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought.
Study: NCT04710472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mentora App
Description: Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria.
Study: NCT06132815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser troughing
Description: Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retraction cord and astringent
Description: Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cordless retraction paste with astringent
Description: The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cordless retraction paste without astringent
Description: The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
Study: NCT05190926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-Treatment for Anorexia Nervosa Recovery (STAR)
Description: Adolescents will use their smartphone to access short 5-10 minute modules that teach them about the function of emotions, ways to regulate challenging emotions, and strategies to improve negative thinking, mood, and reduce eating-disorder symptoms. Module content will include text, images, videos, and interactive questions and quizzes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Present-focused Anorexia Nervosa Coping Treatment (PACT)
Description: Adolescents will use their smartphone to access two brief psychoeducational modules that teach about the common symptoms of AN, common reactions and problems associated with AN, and goals for treatment. Starting in Week 3, adolescents will complete a Daily Diary that will ask them to record life stressors, challenges, and problems, which will serve as a launching point for discussion with their outpatient therapist.
Study: NCT06160648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management according to Mechanical Diagnosis and Therapy
Description: MDT management is based on the patient response to repeated end range movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Management according to the Cervical Spine Clinical Practice Guidelines
Description: CPG management is based on clinical research regarding management of people with neck pain.
Study: NCT05966688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: Multiple oral doses of SPR720 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: Multiple oral doses of SPR720 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Multiple oral doses of azithromycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Multiple oral doses of azithromycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Multiple oral doses of azithromycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Multiple oral doses of ethambutol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Multiple oral doses of ethambutol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Multiple oral doses of ethambutol.
Study: NCT05063773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed reality heads up display
Description: Physician will use a mixed reality headset for image guidance of the procedure
Study: NCT06182982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricolotherapy
Description: Magnetic bal plasters are applied on the ear surface

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: auricolotherapy
Description: Magnetic bal plasters are applied on the ear surface
Study: NCT05928195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute Moderate-Dose Guayusa Extract Supplementation
Description: Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute High-Dose Guayusa Extract Supplementation
Description: Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
Study: NCT05598372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shotblocker
Description: infant pain during vaccination and mother anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lullaby
Description: infant pain during vaccination and mother anxiety
Study: NCT05603234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Monitoring
Description: Reporting symptoms each day via a symptom questionnaire
Study: NCT06373809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of Placenta Derived Stem Cells
Description: Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of Placenta Derived Stem Cells
Description: Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients
Study: NCT05468632

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
Study: NCT05761028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05846685

Intervention type: OTHER
Intervention: Patient Phone Interviews
Description: Collecting perceptions about automated falls-risk screening and referral tool

Intervention type: OTHER
Intervention: Patient Phone Interviews
Description: Collecting perceptions about automated falls-risk screening and referral tool

Intervention type: OTHER
Intervention: Patient In Person Interviews
Description: Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
Study: NCT05915598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right/left discrimination training
Description: Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function.
Study: NCT06252064

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation + Drug therapy
Description: Patients in the Combo group underwent rehabilitation treatment combined with drug therapy: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. Patients included in this group also took drug therapy, particularly Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients in the Reha group underwent rehabilitation treatment: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. The treatment included an initial step, lasting 40 minutes, of Postural Reeducation ending with Stretching exercises of the posterior kinetic chain muscles lasting 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug therapy
Description: The Drug Group had taken Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days. The tablet was taken without chewing and with a glass of water (200 ml). The drug was taken in environments with temperature below 25° C.
Study: NCT04799886

Intervention type: OTHER
Intervention: Semi structured interview
Description: Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
Study: NCT06471400

Intervention type: OTHER
Group type: OTHER
Intervention: interview
Description: patient relatives or legal authorized representatives will be interviewed
Study: NCT04793022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA with Propofol
Description: Total intravenous anesthesia with propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Anesthesia
Description: General anesthesia given with inhaled anesthetics
Study: NCT05025956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Oral Fisetin 20 mg/kg taken for 8 days total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
Study: NCT04639180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib (Apatinib)
Description: Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
Study: NCT05458076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128 A-Dose 1~5 and Ritonavir
Description: Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128 C-Dose 1~3 and Ritonavir
Description: Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128 D-Dose 1 and Ritonavir
Description: Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5
Study: NCT05042310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3541860
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3541860
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered either IV or SC.